Profile data is unavailable for this security.
About the company
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
- Revenue in USD (TTM)130.19m
- Net income in USD-24.41m
- Incorporated2006
- Employees315.00
- LocationHarrow Inc102 WOODMONT BLVD, SUITE 610NASHVILLE 37215United StatesUSA
- Phone+1 (615) 733-4731
- Fax+1 (858) 345-1745
- Websitehttps://www.harrow.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aquestive Therapeutics Inc | 50.58m | -7.87m | 334.84m | 135.00 | -- | -- | -- | 6.62 | -0.1437 | -0.1437 | 0.7691 | -1.55 | 0.8836 | 3.32 | 7.68 | 374,688.90 | -13.75 | -76.63 | -27.78 | -123.85 | 58.82 | 64.24 | -15.56 | -102.95 | 1.87 | -- | -- | -- | 6.09 | -5.59 | 85.54 | -- | -11.42 | -- |
| Q32 Bio Inc | 1.16m | -112.96m | 336.89m | 7.00 | -- | 1.25 | -- | 291.43 | -35.17 | -35.17 | 0.3598 | 22.64 | 0.0074 | -- | -- | 165,142.90 | -55.64 | -34.98 | -62.45 | -37.92 | -- | -- | -7,532.87 | -971.76 | -- | -- | 0.00 | -- | -63.97 | -26.32 | -2,156.96 | -- | -60.90 | -- |
| Caribou Biosciences Inc | 34.48m | -102.07m | 339.58m | 158.00 | -- | 0.9027 | -- | 9.85 | -1.45 | -1.45 | 0.4675 | 4.17 | 0.0856 | -- | 17.14 | 218,208.90 | -25.33 | -- | -27.24 | -- | -- | -- | -296.05 | -- | -- | -19,343.17 | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
| Revance Therapeutics Inc | 234.04m | -323.99m | 342.87m | 534.00 | -- | -- | -- | 1.47 | -3.81 | -3.81 | 2.77 | -1.72 | 0.4414 | 2.33 | 12.00 | -- | -61.11 | -55.55 | -72.36 | -63.20 | 68.23 | -- | -138.43 | -304.96 | 3.29 | -36.36 | 1.54 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
| Mersana Therapeutics Inc | 36.86m | -171.67m | 345.71m | 123.00 | -- | 9.32 | -- | 9.38 | -1.50 | -1.50 | 0.3175 | 0.3057 | 0.1315 | -- | 2.46 | 299,634.20 | -61.27 | -61.68 | -84.73 | -81.35 | -- | -- | -465.80 | -622.19 | -- | -- | 0.408 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Precigen Inc | 6.23m | -95.90m | 348.49m | 202.00 | -- | 2.94 | -- | 55.98 | -0.3933 | -0.3933 | 0.0255 | 0.476 | 0.0339 | -- | 6.62 | 30,816.83 | -52.26 | -31.50 | -72.27 | -38.63 | 1.70 | 44.00 | -1,540.63 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Aura Biosciences Inc | 0.00 | -76.41m | 350.49m | 88.00 | -- | 1.55 | -- | -- | -1.93 | -1.93 | 0.00 | 4.58 | 0.00 | -- | -- | 0.00 | -31.90 | -- | -33.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -44.60m | 351.99m | 19.00 | -- | -- | -- | -- | -10.38 | -10.38 | 0.00 | -1.56 | 0.00 | -- | -- | 0.00 | -94.31 | -86.84 | -178.23 | -130.46 | -- | -- | -- | -769.76 | -- | -15.46 | 1.74 | -- | -- | -- | -5.33 | -- | -- | -- |
| Amarin Corporation plc (ADR) | 306.91m | -59.11m | 353.22m | 275.00 | -- | 0.6369 | -- | 1.15 | -0.145 | -0.145 | 0.7529 | 1.35 | 0.3573 | 0.4192 | 2.32 | 1,116,040.00 | -6.88 | -4.48 | -9.86 | -6.54 | 66.72 | 75.70 | -19.26 | -8.59 | 1.80 | -- | 0.00 | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| Harrow Inc | 130.19m | -24.41m | 353.63m | 315.00 | -- | 4.97 | -- | 2.72 | -0.7448 | -0.7448 | 3.99 | 2.01 | 0.5546 | 4.55 | 6.13 | 413,311.10 | -10.40 | -10.86 | -12.14 | -12.71 | 69.55 | 70.75 | -18.75 | -15.35 | 2.61 | 0.0445 | 0.7223 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Skye Bioscience Inc | 0.00 | -37.64m | 360.61m | 11.00 | -- | -- | -- | -- | -5.69 | -5.69 | 0.00 | -0.1726 | 0.00 | -- | -- | 0.00 | -357.65 | -232.67 | -- | -- | -- | -- | -- | -- | -- | -43.27 | 1.95 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Medifast Inc | 1.07bn | 99.41m | 365.00m | 634.00 | 3.68 | 1.81 | 3.24 | 0.3405 | 9.11 | 9.11 | 98.22 | 18.49 | 3.42 | 3.42 | 245.69 | 1,690,939.00 | 31.76 | 41.25 | 50.60 | 69.38 | 72.37 | 73.20 | 9.27 | 10.06 | 1.84 | -- | 0.00 | 49.18 | -32.94 | 16.43 | -30.75 | 12.25 | 5.59 | 17.72 |
| Nature's Sunshine Products Inc | 445.32m | 15.08m | 365.47m | 814.00 | 25.17 | 2.38 | 12.95 | 0.8207 | 0.7715 | 0.7715 | 22.78 | 8.16 | 1.86 | 1.84 | 38.84 | 547,076.20 | 6.85 | 6.57 | 10.02 | 9.41 | 72.11 | 72.69 | 3.69 | 3.74 | 1.29 | -- | 0.00 | 27.72 | 5.55 | 4.07 | 3,965.64 | -- | 16.73 | -- |
| ADC Therapeutics SA | 69.56m | -240.05m | 366.43m | 273.00 | -- | -- | -- | 5.27 | -2.94 | -2.94 | 0.8528 | -1.80 | 0.1645 | 0.179 | 1.42 | 254,791.20 | -55.47 | -48.41 | -67.39 | -55.63 | 96.36 | -- | -337.16 | -308.62 | 4.73 | -4.70 | 1.55 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Tscan Therapeutics Inc | 21.05m | -89.22m | 366.70m | 154.00 | -- | 2.31 | -- | 17.42 | -2.49 | -2.49 | 0.4421 | 3.15 | 0.0893 | -- | -- | 136,681.80 | -37.87 | -- | -42.07 | -- | -- | -- | -423.86 | -- | -- | -- | 0.1661 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
| Cartesian Therapeutics Inc | 26.00m | -219.71m | 371.60m | 38.00 | -- | -- | -- | 14.29 | -41.77 | -41.77 | 5.03 | -25.87 | 0.1104 | -- | 4.17 | 684,315.80 | -93.31 | -43.66 | -116.36 | -66.84 | -- | -- | -844.91 | -136.35 | -- | -0.5814 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
Data as of Apr 26 2024. Currency figures normalised to Harrow Inc's reporting currency: US Dollar USD
44.66%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Opaleye Management, Inc.as of 28 Mar 2024 | 3.75m | 10.59% |
| Private Capital Management LLCas of 31 Dec 2023 | 2.79m | 7.90% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.03m | 5.73% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.73m | 4.89% |
| Braidwell LPas of 31 Dec 2023 | 1.50m | 4.24% |
| Morgan Stanley & Co. LLCas of 31 Dec 2023 | 1.35m | 3.82% |
| DWS Investments (UK) Ltd.as of 31 Dec 2023 | 747.55k | 2.11% |
| Geode Capital Management LLCas of 31 Dec 2023 | 671.55k | 1.90% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 618.04k | 1.75% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 611.18k | 1.73% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
